Caxton Associates (New York)’s Coherus Oncology CHRS Stock Holding History

Caxton Associates (New York)’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-89,473	Closed	-$335K	–	471
2023 Q3	$335K	Buy	+89,473	New	+$413K	0.05%	295
2023 Q2	–	Sell	-112,186	Closed	-$767K	–	524
2023 Q1	$767K	Buy	+112,186	New	+$871K	0.12%	195
2022 Q3	–	Sell	-12,892	Closed	-$93K	–	497
2022 Q2	$93K	Buy	+12,892	New	+$112K	0.01%	515
2020 Q2	–	Sell	-11,857	Closed	-$192K	–	477
2020 Q1	$192K	Sell	11,857 -7,000	-37%	-$129K	0.04%	355
2019 Q4	$340K	Buy	+18,857	New	+$348K	0.05%	250

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Associates (New York)'s CHRS Position: Q4 2023 in Review

Caxton Associates (New York) sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 89,473 shares — an estimated $335K sold.

Caxton Associates (New York) first reported a position in CHRS in Q4 2019 and held it in 5 quarters. The position peaked at $767K in Q1 2023. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

Caxton Associates (New York) reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
Caxton Associates (New York) sold 89,473 Coherus Oncology shares in Q4 2023, an estimated $335K.
Caxton Associates (New York) first reported a position in Coherus Oncology in Q4 2019 and held it in 5 quarters.
Caxton Associates (New York)'s Coherus Oncology position peaked at $767K in Q1 2023.
156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Caxton Associates (New York)'s 13F filing for Q4 2023, filed 14 Feb 2024.